WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (OTCQB: CVRS), a leading developer of precision vascular robotics, will showcase its CorPath© Vascular Robotic System during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2014 meeting, September 13 – 17 in Washington, D.C. Throughout the meeting, Corindus will highlight occupational safety and robotic precision during percutaneous coronary intervention (PCI) procedures, including radiation exposure reduction by robotic-assisted PCI.
Sessions highlighting the CorPath System:
- September 13 – Poster reviewing complex PCI performed with robotic-assistance (5:00-7:00pm)
- September 14 – Live Robotic-assisted PCI case presentation in Main Arena (11:00am)
- September 15 – CorPath discussed during Session 1: Cath Lab Technology Evolution: Imaging Integration and Radiation Reduction (2:00-3:08pm)
- September 16 – Corindus sponsored breakfast symposium “Robotic PCI: Precision and Protection from Occupational Hazards” (6:30-8:00am)
- CorPath System in a simulator environment throughout the meeting at the Corindus Vascular Robotics Booth #1342 in the Expo hall
- Daily "Hot Topic Lunch" sessions to discuss radiation control will be held in room 142.
The Corindus CorPath System is the first FDA-approved medical device to bring robotic precision and accuracy to help optimize clinical outcomes during coronary angioplasties. Additionally, the CorPath System reduces radiation exposure for the interventional cardiologist.
“Radiation poses a risk to the health and safety of interventional cardiologists today; however, use of the CorPath System has proven to reduce radiation exposure while providing robotic precision during PCI,” said David Handler, President and CEO of Corindus Vascular Robotics. “Radiation exposure as an occupational hazard among interventional cardiologists is becoming a growing concern that must be addressed, and Corindus is dedicated to advocating for the safety of these physicians and their patients. TCT provides an ideal forum for us to bring these issues to the forefront.”
Recent studies and published articles pointing to the risks associated with traditional PCI procedures include:
- A study by Venneri, et al. highlighting that interventional cardiologists experience the highest amounts of radiation exposure of any medical professionals.
- A study by Roguin, et al. which linked radiation exposure to the prevalence of brain tumors on the left-side of the brain. The study found that 86% of interventional cardiologists who self-reported brain tumors had the malignancy on the left side, which is the side closest to the x-ray source during procedures.
- A study reported by Vano, et al. reveals that radiation exposure has led to 50% of interventional cardiologists displaying significant posterior subcapsular lens changes, a precursor to cataracts, which are typical of ionizing radiation exposure.
For more information on the symposium, “Robotic PCI: Precision and Protection from Occupational Hazards,” click here.
TCT Meeting attendees can register here to use the CorPath System in a simulator environment at the Corindus Vascular Robotics Booth #1342.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. (OTCQB: CVRS) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The Company’s FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.